BioCryst Pharmaceuticals, Inc.
corporate_fare Company Profile
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BCRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BCRX spans 10-Q, 8-K, 8-K/A, 10-K.
Recent high-impact activity:
- BioCryst 10-Q Details Q3 Profit, $375M Liquidity and Specialty Pharmacy Inventory Boost
- BioCryst Q3 Revenue $180.3M, Net Income $37.9M; Raises Total Revenue Guidance
- BioCryst Swings to $37.9M Third-Quarter Profit
- FDA Approves ORLADEYO Oral Pellets for Adults and Teens With HAE
- Japan Approves ORLADEYO for Pediatric HAE, Expanding Market
Financial Snapshot
Short Interest & Short Volume
5.09 days to coverFINRA reported short interest of 27,637,852 shares in BCRX as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 47.9% of BCRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.